Quick Answer
DNA X, Inc. reported Research And Development Expense of $14.24 million for the year ending 2024.
- DNA X, Inc. showed an increase of +703.3% in Research And Development Expense from 2023 to 2024.
- This data is from DNA X, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $5.14 million | Q2 2018: $5.63 million | Q3 2018: $6.00 million | Q1 2019: $6.96 million | Q2 2019: $7.38 million | Q3 2019: $6.65 million | Q1 2020: $3.94 million | Q2 2020: $3.26 million | Q3 2020: $3.39 million | Q1 2021: $4.66 million | Q2 2021: $3.67 million | Q3 2021: $5.49 million | Q1 2022: $4.17 million | Q2 2022: $2.72 million | Q3 2022: -$135.0 thousand | Q1 2023: $105.0 thousand | Q3 2023: $741.0 thousand | Q1 2024: $456.0 thousand | Q2 2024: $557.0 thousand | Q3 2024: $715.0 thousand | Q1 2025: $1.63 million | Q2 2025: $909.0 thousand | Q3 2025: $181.0 thousand.
- Over the full 7 years of available data (2018 to 2024), DNA X, Inc.'s Research And Development Expense has declined by 38.8%.
- Historical annual values: Fiscal year 2024: $14.24 million | Fiscal year 2023: $1.77 million | Fiscal year 2022: $7.97 million | Fiscal year 2021: $17.70 million | Fiscal year 2020: $16.22 million | Fiscal year 2019: $26.06 million | Fiscal year 2018: $23.25 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: